DrugPatentWatch Database Preview
ADHANSIA XR Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Adhansia Xr patents expire, and when can generic versions of Adhansia Xr launch?
Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-two patent family members in sixteen countries.
The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for ADHANSIA XR
| International Patents: | 22 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ADHANSIA XR |
| DailyMed Link: | ADHANSIA XR at DailyMed |
Pharmacology for ADHANSIA XR
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for ADHANSIA XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-006 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-006 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-001 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-004 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-005 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-002 | Feb 27, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADHANSIA XR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2936741 | Start Trial |
| Canada | 2936746 | Start Trial |
| Israel | 252011 | Start Trial |
| Canada | 2936740 | Start Trial |
| Australia | 2015337779 | Start Trial |
| Canada | 2902911 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
